ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Lung Cancer trials near Hanyang, Seoul, KOR:

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 83 other locations

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Trastuzumab deruxtecan

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 49 other locations

Locations recently updated

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: MGY825

Phase 1

Novartis
Novartis

Seoul, Korea, Republic of and 12 other locations

and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Etrumadenant
Drug: Zimberelimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Seoul, Korea, Republic of and 46 other locations

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Seongnam Si, Gyeonggi Do, Korea, Republic of and 54 other locations

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).

Enrolling
Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Drug: Placebo
Drug: Tarlatamab

Phase 3

Amgen
Amgen

Seoul, Korea, Republic of and 77 other locations

This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 3

Arcus Biosciences
Arcus Biosciences

Seoul, Korea, Republic of and 167 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 209 other locations

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Platinum-Based Doublet

Phase 2

Gilead Sciences
Gilead Sciences

Seoul, Korea, Republic of and 33 other locations

locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (CTM-1 Lyo-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 21 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems